SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Bayhill Therapeutics, Inc. Presents Data From a Phase II Trial of BHT-3009 in Multiple Sclerosis at American Academy of Neurology 60th Annual Meeting